HEALTH-RELATED QUALITY OF LIFE IN ONCOLOGY – ARE WE GETTING BETTER?
Author(s)
Byrne K1, Simpson S2, Bennett B2, Rider A3, Hallworth P1, Desai T2, Cocks K4
1Adelphi Real World, Bollington, Cheshire, UK, 2Adelphi Values Ltd, Bollington, Cheshire, UK, 3Adelphi Real World, Cheshire, UK, 4Adelphi Values, Bollington, Cheshire, UK
OBJECTIVES: With recent advances in the treatment of cancer we would hope to see improvements in survival rates and greater health-related quality of life (HRQoL). The main aim of this analysis was to examine HRQoL scores across a sample of EU cancer patients. Comparisons were made between existing norms based on a US cancer population. METHODS: HRQoL data across breast, gastric, melanoma, non-small cell lung and prostate cancers were collected through the Adelphi Real World Disease-Specific Programmes (DSPs). All data were collected from EU patients between January 2015 and March 2017 and included the FACT instrument, resulting in a total sample of 4899 patients. Analysis included comparisons between the DSP and existing US cancer population norms. RESULTS: The EU sample had similar population characteristics to the published population norms with respect to age, gender and ECOG status but consisted of a wider sample of cancer types (including haematological cancers). Using minimum important differences (MIDs) of 3 points for FACT domain and 7 points for total FACT-G score, comparisons between the DSP data and US population norms identified several differences in domain and FACT-G scores between the EU and population norms based on MIDs. Exceeding MIDs were noted across social well-being (SWB), emotional well-being (EWB), functional well-being (FWB) and overall FACT-G, but not for physical well-being (PWB). In all these cases the EU data were consistently lower than the cancer population norm data. CONCLUSIONS: Two potential reasons for the observed differences are identified; one reason that may account for the differences is that HRQoL of cancer patients has decreased since the norm data was published, the other reason may be that the population norms may be region-specific. Further work comparing specific cancer types will also be presented. These reasons are further explored with respect to the changing therapeutic environment within oncology.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN245
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology